An interventional study of LLM-Enabled Co-management in Hypertension, Diabetes and Dyslipidemia, sponsored by First Hospital of China Medical University. Active, not recruiting at 6 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by First Hospital of China Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.
Among the 410 studies in Hypertension with a site in China, this one is the 19th largest by planned enrollment of the 308 interventional ones that give a count, is one of 38 that started in 2026, is one of 146 with no phase, reaches primary completion later than 92 of the 147 other live ones, and was the 363rd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China Medical University, China · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
410 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 23 · Phase 3 50 · Phase 4 76
First in 1998; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,800 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 308 interventional studies, 1,000 across the 102 observational. Of the 161 that completed or were terminated, 22 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 410 have an industry lead sponsor. The 10 most frequent:
First Hospital of China Medical University is the lead sponsor of 62 studies on the registry; 34 are open to participants now.
First Hospital of China Medical University has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
47 of the studies in Hypertension with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
Add all 47 to your calendar (.ics) → With an account.
Among the 410 studies in Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effectiveness of a large language model (LLM)-supported, community-based integrated management model in improving cardiometabolic multimorbidity control among adults with hypertension and coexisting diabetes or dyslipidemia. Adopting an interventional study design, eligible patients will be recruited to compare the disease control indicators between LLM-assisted management and conventional management, so as to verify the effectiveness and safety of the former.
Inclusion Criteria:
Participating communities must meet all of the following criteria:
Eligible participants must fulfill all of the following conditions:
Exclusion Criteria:No specific exclusion criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LLM-enabled community physicians delivered integrated, guideline-based management
Other: LLM-Enabled Co-management
Community physicians provided routine care according to local primary health service standards
The intervention is a LLM-enabled, community-based integrated management strategy for cardiometabolic multimorbidity. The LLM system functions as the central intelligence layer, integrating multi-condition clinical information, delivering real-time decision support, coordinating care workflows, and facilitating continuous patient engagement. Within this LLM-enabled framework, community physicians-after standardized training-serve as the core executors of care, delivering guideline-based pharmacologic treatment, lifestyle counseling, and structured monitoring of coexisting cardiometabolic conditions. Policy-aligned performance incentives are used to support physician engagement and implementation fidelity, without altering medication access or underlying clinical protocols. The LLM-enabled intervention is implemented through the HyperMind system, an integrated platform that simultaneously supports clinicians, patients, and health-system oversight.
The between-group difference in the proportion of participants achieving simultaneous control of hypertension and either diabetes or dyslipidemia.
Simultaneous control is defined as BP \< 130/80 mmHg and at least one of the following: HbA1c \< 7.0% or LDL-C \< 2.6 mmol/L (100 mg/dL), with a stricter threshold of \< 1.8 mmol/L (70 mg/dL) for participants with cardiovascular disease(CVD).
Time frame: 6 months after baseline
Net changes in estimated 10-year risk for atherosclerotic CVD.
Net change in estimated 10-year atherosclerotic cardiovascular disease risk.
Time frame: 6 months after baseline
Proportion of participants achieving control of individual risk factors: BP < 130/80 mmHg (or < 140/90 mmHg); HbA1c < 7.0%; and LDL-C < 2.6 mmol/L (100 mg/dL) or < 1.8 mmol/L (70 mg/dL) for those with CVD.
The proportion of participants achieving target control of each individual risk factor, including blood pressure, HbA1c, and LDL-C.
Time frame: 6 months after baseline
Mean systolic blood pressure changes.
Mean systolic blood pressure changes of participants.
Time frame: 6 months after baseline
Mean diastolic blood pressure changes.
Mean diastolic blood pressure changes of participants.
Time frame: 6 months after baseline.
Mean HbA1c changes.
Mean HbA1c changes of participants.
Time frame: 6 months after baseline.
Mean LDL-C changes.
Mean LDL-C changes of participants.
Time frame: 6 months after baseline.
Proportion of participants achieving simultaneous control of BP, HbA1c, and LDL-C.
The proportion of participants achieving simultaneous control of blood pressure, HbA1c, and LDL-C.
Time frame: 6 months after baseline
Awareness and treatment rates for hypertension, diabetes, and dyslipidemia.
Rates of disease awareness and treatment for hypertension, diabetes, and dyslipidemia.
Time frame: 6 months after baseline
Proportion of participants receiving integrated, guideline-based management of all indicated conditions.
The proportion of participants receiving integrated, guideline-based management for indicated conditions.
Time frame: 6 months after baseline
Mean health expenditures and within-trial cost-utility.
Mean health care expenditures and within-trial cost-utility outcomes.
Time frame: 6 months after baseline
Changes in treatment adherence.
Change in treatment adherence among participants.
Time frame: 6 months after baseline
Improvements in behavioral risk factors (e.g., diet, physical activity, tobacco use, lifestyle intervention uptake).
Changes in behavioral risk factors including diet, physical activity, and tobacco use.
Time frame: 6 months after baseline
Patient-reported outcomes related to satisfaction.
Patient-reported satisfaction with LLM will be assessed using a structured scale.
Time frame: 6 months after baseline
Patient-reported outcomes related to self-management.
Patient-reported self-management will be assessed using a structured scale.
Time frame: 6 months after baseline.
Patient-reported outcomes related to quality of life.
Patient-reported quality of life will be assessed using a structured scale.
Time frame: 6 months after baseline.
Adoption and utilization of the LLM system by physicians and patients.
The extent of physician and patient adoption and use of the LLM-based system.
Time frame: 6 months after baseline
Patterns of AI-assisted recommendations and digital interactions.
The patterns of Artificial Intelligence(AI)-assisted recommendations and related digital interactions generated during the study.
Time frame: 6 months after baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 10 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Hospital of China Medical University